Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ever Fortune.AI CoROCO:6841 +2.47%77 EV-to-EBITDA is 37.38 as of Sep. 06, 2026, which is 7% above its 10-year median of 34.88. GuruFocus rates ROCO:6841 with a GF Score™ of 77/100 and a GF Value™ of NT$108.23 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 513 Healthcare Providers & Services companies, Ever Fortune.AI Co ranks worse than 89.28% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ever Fortune.AI Co's enterprise value is NT$4,742.0 Mil.
Ever Fortune.AI Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$126.9 Mil. Therefore, Ever Fortune.AI Co's EV-to-EBITDA for today is 37.38.
The historical rank and industry rank for Ever Fortune.AI Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6841'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2177.79 Med: 34.88 Max: 210.54
Current: 37.38
During the past 8 years, the highest EV-to-EBITDA of Ever Fortune.AI Co was 210.54. The lowest was -2177.79. And the median was 34.88.
ROCO:6841's EV-to-EBITDA is ranked worse than 89.28% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 10.51
vs ROCO:6841: 37.38
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ever Fortune.AI Co (ROCO:6841) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ever Fortune.AI Co's PE Ratio (TTM) for today is calculated as:
Ever Fortune.AI Co's share price for today is NT$54.00.
Ever Fortune.AI Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ever Fortune.AI Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6841 vs VEEV, BTSG, TEM: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Ever Fortune.AI Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ever Fortune.AI Co EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ever Fortune.AI Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ever Fortune.AI Co's EV-to-EBITDA falls into.
Ever Fortune.AI Co's current Enterprise Value is NT$4,742.0 Mil.
Ever Fortune.AI Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$126.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ever Fortune.AI Co (ROCO:6841) has a EV-to-EBITDA of 37.38 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ever Fortune.AI Co. This is near median its historical median of 34.88. According to the industry distribution chart, Ever Fortune.AI Co ranks #458 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 89.3%.
Is Ever Fortune.AI Co's EV-to-EBITDA too high?
Ever Fortune.AI Co's current EV-to-EBITDA of 37.38 is near median its 10-year median of 34.88. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.51. Ever Fortune.AI Co's value of 37.38 is 255.7% above this industry median. Based on the distribution chart, Ever Fortune.AI Co ranks #458 out of 513 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Ever Fortune.AI Co has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ever Fortune.AI Co's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Ever Fortune.AI Co ranks #458 out of 513 companies for EV-to-EBITDA. This places Ever Fortune.AI Co in the lower half of its industry. The industry median EV-to-EBITDA is 10.51. Ever Fortune.AI Co's value of 37.38 is 255.7% above this benchmark. While the company's 10-year median is 34.88 vs. the industry median of 10.51, Ever Fortune.AI Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.51, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ever Fortune.AI Co's current EV-to-EBITDA of 37.38 is 255.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ever Fortune.AI Co. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ever Fortune.AI Co's current EV-to-EBITDA is 37.38, which is near median its own 10-year median of 34.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ever Fortune.AI Co stock overvalued right now?
Based on GuruFocus' analysis, Ever Fortune.AI Co (ROCO:6841) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$108.23, compared to a current price of NT$54.00 — trading 50.1% below its estimated fair value. The current EV-to-EBITDA is 37.38, which is near median its 10-year median of 34.88 and 255.7% above the Healthcare Providers & Services industry median of 10.51. Ever Fortune.AI Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ever Fortune.AI Co (ROCO:6841), the current EV-to-EBITDA is 37.38 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ever Fortune.AI Co (ROCO:6841) Overvalued in 2026?
Based on GuruFocus' analysis, Ever Fortune.AI Co stock appears to be undervalued.
The current stock price of NT$54.00 is trading 50.1% below its estimated GF Value™ of NT$108.23.
GuruFocus considers Ever Fortune.AI Co to be Significantly Undervalued.
Key valuation signals for ROCO:6841:
EV-to-EBITDA: 37.38 (near median its 10-year median of 34.88)
GF Value™: NT$108.23 vs. price of NT$54.00 (50.1% below fair value)
Industry Position: 255.7% above the Healthcare Providers & Services median (#458 of 513)
No single metric tells the full story. See the ROCO:6841 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ever Fortune.AI Co Ltd is composed of establishing a cloud medical platform based on medical Big data, and to provide customized medical artificial intelligence solutions and services in various biomedical fields. The results both provide a professional second opinion for doctors and assist clinical doctors in making a medical diagnosis, which in turn raises the speed, accuracy, and efficiency of medical decisions. The products of the company include: Medical Artificial Intelligence, Cloud Biomedical Platform, and Medical Big Data. Its segments are: Medical AI Department; Biotechnology Department; and Others, where maximum revenue is derived from Biotechnology Department segment. Geographically, it operates in Taiwan, U.S.A., and Vietnam, of which maximum revenue is generated from Taiwan.
77GF Score
Get the complete analysis for ROCO:6841
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6841 has been successfully added to your 
